Vitamin K2

Vitamin K2 activates the proteins that steer calcium into bone and keep it out of artery walls — the mechanism is well established and the biomarker evidence genuinely strong, but the trials measure scans and markers rather than heart attacks or deaths, and they are split: positive results on artery stiffness, coronary calcium and bone loss, against null ones on heart-valve calcium, bone density in women with thinning bones, and calcification in kidney disease. It is a cheap, very safe pairing with vitamin D3 for bone and vascular health, not the proven life-extender the supplement market implies.

Vitamin K comes in two families. K1 (phylloquinone), from leafy greens, is what the liver uses to make clotting factors, and ordinary diets supply plenty of it. K2 (the menaquinones), from fermented foods and animal fats, is the form that reaches tissues outside the liver — the vasculature, the skeleton — and it is chronically thin in modern Western diets. Almost everything interesting about K2 for longevity sits in that extrahepatic role, and almost none of it is captured by the official intake numbers, which were set from typical intakes and are enough for blood clotting.

What K2 actually does: the calcium traffic problem

Vitamin K is the required cofactor for one specific chemical step — carboxylation — that switches on a small family of "Gla proteins." Until they are carboxylated, these proteins are inert; they cannot bind calcium. Two of them carry the whole longevity argument:

  • Osteocalcin, made by bone cells, pulls calcium into the skeletal matrix.
  • Matrix Gla Protein (MGP), made in artery walls, sweeps calcium out of soft tissue and is the most potent natural brake on vascular calcification known.

When K2 status is low, both proteins circulate in their uncarboxylated, switched-off form. You can absorb calcium perfectly well (vitamin D handles that) and still lack the machinery to route it — the setup behind the so-called "calcium paradox," where the same person loses calcium from bone while depositing it in arteries.[1] The uncarboxylated form of MGP (dp-ucMGP) is measurable in blood and predicts arterial stiffness and cardiovascular events — which is why K2 has a strong biomarker case even where the hard-outcome trials are missing. (Strong — for the carboxylation mechanism and the biomarker's predictive value; whether moving the biomarker changes outcomes is the open question the trials below wrestle with.)[2]

This is the same routing logic that makes K2 part of the calcium triad and the bone-density stack — it doesn't add calcium, it decides where calcium goes.

MK-4 versus MK-7: why the form matters

The two K2 forms worth knowing behave very differently in the body. MK-4, like K1, is cleared from the blood within about an hour or two; MK-7 stays for several days.[3]

FormHalf-lifeDosingEvidence profile
MK-4 (menatetrenone)About 1–1.5 hoursNeeds large, multiple daily dosesThe form behind almost all the fracture-endpoint trial data, at pharmacological doses (~45 mg/day) in Japanese osteoporosis cohorts — but that literature is retraction-contaminated (see below). Nutritional doses don't raise blood levels at all.
MK-7 (menaquinone-7)Several daysOnce daily, 90–180 µgStandard nutritional doses produce sustained, measurable blood levels and more complete protein carboxylation. Strong mechanism and biomarker data; the better-studied surrogate-endpoint trials use this form.

The practical upshot: a small daily MK-7 dose maintains continuous carboxylation in a way that nutritional MK-4 cannot, because MK-4 is cleared within hours and absorbed poorly at food-level doses.[4] MK-4's fracture data comes from doses roughly 250× higher than a supplement capsule — a Japanese prescription protocol, not a longevity dose — and it does not bear the weight usually placed on it. The meta-analysis that reported large fracture reductions pooled seven Japanese menaquinone trials, including trials from a Japanese research group whose work has since faced serious integrity concerns; many of that group's menatetrenone papers have been retracted. The meta-analysis now carries a formal correction warning about its conclusions, and its own senior author published a caution to readers.[5] [6] [7] A second, unrelated Japanese osteoporosis trial that included a vitamin K2 arm has since had its integrity questioned too.[8] The one large trial free of integrity concerns — 4,378 women with osteoporosis, half given 45 mg/day on top of calcium against calcium alone, open-label with blinded assessment, for three years — missed its primary endpoint in both strata and had more adverse events on the drug,[9] and a pooled analysis of menatetrenone trials found a small gain in spine density but no significant drop in spinal fractures.[10] The most careful re-analysis, by the same York team that issued the caution and with every trial from the suspect group removed, found no reliable effect of vitamin K on bone density or spinal fractures in post-menopausal or osteoporotic women. It found possibly fewer clinical fractures of any kind (2.2% vs 3.1% of participants), but that result lost statistical significance when only the best-quality trials were counted, meaning no effect at all could no longer be ruled out, so any benefit is unproven. Most of the fracture trials behind it used 45 mg/day of MK-4, not supplement-dose MK-7, and a 2020 correction that removed one more questioned trial left these results essentially unchanged.[11] [12] For a healthy adult, MK-7 at 90–180 µg/day is the sensible default.

The cardiovascular evidence: strong mechanism, thinner outcomes

This is where honesty matters most, because the marketing runs well ahead of the trials.

The observational signal is real but observational. The landmark population data is the Rotterdam Study, which followed 4,807 adults for up to a decade: those in the highest third of dietary menaquinone (K2) intake had roughly half the coronary-heart-disease mortality and severe aortic calcification of the lowest third — while K1 intake showed no association at all, neatly fitting the extrahepatic mechanism.[13] But this is a dietary cohort: people eating more K2 (from cheese and fermented foods) differ in many ways, and no observational study can prove the K2 itself did the work.

Two Dutch trials are positive — both on surrogate endpoints. (Moderate.) The first was a three-year, double-blind, placebo-controlled trial that gave 244 healthy postmenopausal women 180 µg/day of MK-7 and found it not only halted the expected age-related arterial stiffening but modestly reversed it, measured by carotid stiffness and pulse-wave velocity.[14] The second, reported in 2026, moved a calcification imaging endpoint in people with heart disease. It randomized 180 patients with symptomatic coronary artery disease and moderate calcium scores at the start (50 to 400 on the Agatston scale) to MK-7 360 µg/day or placebo for two years, and analyzed 167. On a coronary artery calcium CT scan, the median score went from 135 to 184 on MK-7 and from 145 to 214 on placebo over two years, a statistically significant difference.[15] The authors say MK-7 "may slow calcification", that its clinical significance "remains to be determined", and that a large trial with hard outcomes is needed; an accompanying editorial asks whether calcium-score progression is a useful outcome for trials at all.[16] Both Dutch trials measured risk markers rather than heart attacks or deaths.

The Danish trials are split, and the kidney-disease story is worse. In the first, 365 older men with calcified aortic valves took 720 µg/day of MK-7 plus vitamin D for two years and showed no effect on valve calcification progression, even though the dp-ucMGP biomarker fell as expected.[17] A companion report from the same study, covering 304 men with no known heart disease, found that coronary calcium did not slow significantly overall. It did rise more slowly in men who started with heavy calcification (a calcium score of 400 or more), and the combined count of heart attacks, artery-opening procedures and deaths was lower on the supplement (1.9% vs 6.7%), but the authors call both findings only hypothesis-generating.[18] A second Danish trial then tested that lead directly. In 398 people with heavy coronary calcification (a score of 400 or more; median age 71, 30% women), the same 720 µg of MK-7 plus vitamin D for two years slowed the build-up: the calcium score rose by an average of 196 points, against 248 on placebo, about a fifth less build-up.[19] Like the Dutch trials, this measured a risk marker, not a reduction in heart attacks or deaths. In chronic kidney disease — where patients have the worst vascular calcification and the highest dp-ucMGP, making them the obvious test case — K2 reliably lowers dp-ucMGP, but a pooled analysis of ten trials found that calcification scores on scans did not change even as the biomarkers improved. Results on arterial stiffness are mixed: an open-label trial in dialysis patients (one where everyone knew who was getting the supplement; MK-7 375 µg/day for 24 weeks) slowed stiffening, while a 159-patient kidney-disease trial found no improvement. One clinical review sums this up as no unambiguous cardiovascular protection.[20] A 2026 review by kidney specialists judged that K2 had not yet given reproducible benefits on calcification scans, and that the somewhat more consistent, though still mixed, imaging signal comes from vitamin K1, mainly in dialysis patients given high doses; neither form has yet reduced heart attacks, strokes or deaths, and the few trials that tracked such events were too small to tell.[21] A pooled analysis of 14 earlier trials (1,533 patients in all, by a nephrology team) found a small slowing of coronary calcium, about 17 points on the Agatston scale. The 95% confidence interval, the range the true effect plausibly lies in, ran from about 34 points to almost zero, so the effect is only just distinguishable from none, and the analysis predates both 2026 coronary trials.[22] The biomarker moves reliably; calcification on scans moves a little in some trials and not in others; and no trial has yet been large enough to show fewer heart attacks or deaths. That gap is the honest centre of the K2 story.

Industry supply does not explain the split. The positive Dutch trials used MK-7 from the maker NattoPharma (Gnosis by Lesaffre): its MenaQ7 product in the stiffness trial, and free tablets in the coronary trial. But the null Danish valve trial also got its tablets, placebo included, free from MK-7 makers, Kappa Bioscience and Orkla Care.[23] Differences in who was studied, the dose and what was measured are more plausible explanations, though none has been tested directly.

The longevity signal, honestly localized. (Moderate for the association; unproven as cause.) Beyond the natto and Rotterdam diet cohorts, the cleaner evidence comes from blood levels rather than food-frequency questionnaires. Pooling individual data from three US cohorts, adults with the lowest circulating vitamin K1 had about a fifth higher all-cause mortality than those with ample levels — but, tellingly, no significant excess of cardiovascular events specifically.[24] The vascular biomarker points the same way: in a 15-year study of about 700 adults aged 50 to 89 in northern Italy, higher dp-ucMGP (a sign of poorer vitamin K status in the vessel wall) predicted more cardiovascular disease and, more strongly, death from any cause, but not heart attacks or sudden cardiac death; the link held after accounting for diet quality.[25] Both findings are observational, both point more to overall mortality than to heart attacks, and neither proves cause: the low-vitamin-K1 signal could reflect a diet poorer in vegetables, and high dp-ucMGP may simply mark poorer general health. No trial has shown that raising vitamin K status, or lowering dp-ucMGP, actually lowers mortality.

The bone evidence: maintenance, not dramatic gains

The same Knapen cohort showed that 180 µg/day of MK-7 over three years significantly slowed the loss of bone mineral density (BMD) and content at the lumbar spine and femoral neck versus placebo. (Moderate, for the maintenance effect.)[26] But a comparable three-year trial in postmenopausal women who already had osteopenia — and who were all taking background calcium and vitamin D — found the opposite: a higher MK-7 dose switched on osteocalcin just as expected, yet bone density fell equally in both arms, with no benefit at any site. (Moderate, for the null.)[27] The likeliest explanation for the split is that MK-7 helps most in healthy bone with thin vitamin K status, and adds little once calcium and vitamin D are already replete or bone is frankly diseased. Meta-analytic data confirm K2 shifts bone-turnover markers in a favourable direction — chiefly by converting uncarboxylated osteocalcin to its active form — though that analysis measured no bone-density or fracture outcomes.[28] Pooled trials in middle-aged and older adults show a small bone-density gain at the lumbar spine, significant in women,[29] and in the most careful analysis that spine gain shrank to non-significance when only the best-quality trials were counted, with no consistent effect at other sites.[30] Pooling eight trials (971 people), vitamin K plus vitamin D gave a small increase in total bone density and lowered inactive (uncarboxylated) osteocalcin compared with control or no-treatment groups, but the analysis did not test whether the pair beats vitamin D alone,[31] and in the three-year Rønn trial, adding MK-7 to vitamin D and calcium changed neither bone density nor bone-turnover markers.[32]

The realistic framing: K2 is a supporting nutrient for bone, not a primary driver. The dominant osteogenic stimulus is mechanical — heavy resistance training and impact loading do far more for bone than any micronutrient. K2's job is to make sure the calcium you do absorb is directed correctly. See Bone density.

Food sources: why supplementation even comes up

K2 is genuinely scarce in Western diets, which is the real argument for a supplement.

  • Natto (fermented soybeans) is in a class of its own — a typical 50 g serving carries about 380 µg of MK-7, an order of magnitude beyond any other common food. Habitual natto eaters show higher carboxylated osteocalcin and modestly higher bone density.[33] The mortality signal comes from separate Japanese cohorts (Weak–Moderate — observational, and natto-eaters differ in diet and lifestyle): across ~93,000 adults followed nearly 15 years, fermented soy — but not unfermented soy — was tied to lower all-cause mortality, and natto specifically to lower cardiovascular mortality,[34] while a 15-year cohort of elderly Japanese men linked habitual natto intake to lower all-cause mortality (about 40% lower in the moderate-intake group).[35] See Fermented foods.
  • Aged and fermented cheeses are the main Western source, varying widely by culture and ripening. Aged Dutch cheeses (Gouda, Edam), Munster and Camembert are among the richest, Emmental is moderate; Brie, Gruyère, mozzarella and feta are low, and parmesan has almost none.[36] This K2 content is part of why fermented dairy reads as cardiovascular-neutral-to-favourable despite its saturated fat. See Dietary fats.
  • Egg yolk, butter, and dark poultry meat supply MK-4, but in amounts far below what nutritional studies suggest is needed to shift the proteins.

If you eat natto regularly, you don't need a K2 supplement. Almost no one outside Japan does.

Dose, safety, and the one real caveat

Dose. 180 µg/day of MK-7 is the dose used in the positive three-year trial in healthy postmenopausal women (reported for both arteries and bone), and 90–180 µg/day is what the rest of this site recommends when pairing with D3. Trials at higher doses (about 360–720 µg/day) studied other groups, such as women with thinning bones, older men, and people with heart disease or heavy coronary calcification, and gave mixed results: a 375 µg bone trial and a 720 µg heart-valve trial were null, while two heart trials, at 360 and 720 µg, slowed the build-up of coronary calcium. No trial has compared doses head to head, so there is no demonstrated advantage above roughly 180 µg/day for healthy adults; specialist osteoporosis protocols sometimes go higher.

The official intake numbers are lower. US authorities never set a full recommended dietary allowance for vitamin K because the data were too thin; they set only an Adequate Intake (120 µg/day for men, 90 µg/day for women), based on what healthy people typically eat.[37] Intakes like that keep the liver's clotting factors fully active but leave roughly 20–30% of osteocalcin and MGP uncarboxylated in adults who don't supplement; fully switching on those extrahepatic proteins takes more vitamin K than clotting does.[38] That gap — enough for clotting, short for the bone and vascular proteins — is the core argument for a modest MK-7 supplement, and it is why status is tracked with a dedicated blood marker for each tissue's uncarboxylated protein: PIVKA-II (undercarboxylated clotting factors) for clotting, uncarboxylated osteocalcin for bone, and dp-ucMGP for the vasculature.

Safety is excellent. (Strong.) Natural vitamin K has no established toxicity, and the US Food and Nutrition Board set no upper limit for it because of its low potential for toxicity.[39] The supplement industry's trade association, the Council for Responsible Nutrition, reviewed more than 40 trials in 2025 and named 375 µg/day of MK-7 as the highest daily intake for adults with good safety evidence behind it (a "highest observed intake", not an upper limit), finding no meaningful effect on clotting in people not taking warfarin-type drugs.[40] An earlier independent review by the US Pharmacopeia also found that MK-7 supplements carry no serious health risk.[41] (Synthetic vitamin K3, menadione, is a different molecule — cytotoxic and not used in human supplements.)

The one caveat that matters: warfarin and other vitamin-K-antagonist anticoagulants. These drugs work by blocking vitamin K recycling, so supplemental K2 directly opposes them, and people taking them are advised to keep their vitamin K intake steady because sudden changes can strengthen or weaken the drug's effect.[42] The amounts involved are small. In a study of 15 healthy volunteers given acenocoumarol (a warfarin-type drug), 10 µg/day of MK-7 lowered the international normalised ratio (INR, the standard measure of how strongly the blood is thinned) to a clinically relevant degree in at least 40% of them, and 20 µg/day did so in at least 60%; at 45 µg/day, still well below a typical 90–180 µg supplement, the group's average INR fell by about 40%.[43] If you take warfarin (or acenocoumarol, phenprocoumon), do not start K2 without your prescriber and INR monitoring. The newer direct oral anticoagulants (apixaban, rivaroxaban, dabigatran) work through a different mechanism that does not involve vitamin K, so no interaction is expected.

What is not established

The source literature for K2 is full of dramatic longevity claims that don't survive scrutiny, and it's worth naming them so you can discount the marketing. (Weak / preliminary throughout — observational data, animal studies, or small trials with null or marginal results.)

  • Telomeres. A single cross-sectional analysis found higher dietary vitamin K associated with marginally longer telomeres (about 0.2 base pairs per µg).[44] This is observational, tiny, and not a basis for any claim that K2 slows cellular aging.
  • Sirtuins / lifespan extension. K2 extends lifespan in nematode (C. elegans) models via a stress-response pathway.[45] Worm data is hypothesis-generating, not evidence for humans.
  • Brain and cognition. MK-4 is the dominant K vitamer in brain tissue, and post-mortem cohorts link higher brain MK-4 to less Alzheimer pathology — but this is observational, and any cognitive benefit in living humans is unproven.[46]
  • Muscle and physical function. In a small 12-week randomized trial in 71 healthy young and older adults, MK-7 (240 µg/day) did not change muscle strength, physical function, soreness or inflammation during recovery from a hard bout of resistance exercise; a few signals that differed between the age groups (in muscle response timing and activation, and in IL-6 and creatine kinase, markers of inflammation and muscle damage) were flagged as worth further study. One author had research funding from a K2 maker.[47]
  • Insulin sensitivity and metabolic health. Osteocalcin biology hints at a glucose connection. An early meta-analysis of eight randomized trials found no effect of vitamin K on insulin sensitivity, fasting glucose or fasting insulin.[48] Later pooled trials found a small improvement in fasting glucose and insulin resistance, though not in fasting insulin,[49] somewhat larger in an analysis limited to people with prediabetes or type 2 diabetes, whose authors note that the trials are few and of moderate quality.[50] Not a reason to take K2 for blood sugar.

Treat these as mechanism and curiosity, not as reasons to supplement.

The practical short version

  • If you take vitamin D3 for bone or already supplement calcium, add MK-7 at 90–180 µg/day. It's cheap, very safe, and biologically coherent — it directs the calcium D helps you absorb. See Vitamin D and Calcium.
  • If you eat natto regularly, skip the supplement — a single serving carries more MK-7 than a typical 90–180 µg supplement.
  • Take it with a fat-containing meal (K2 is fat-soluble) and pair it with adequate magnesium for the full bone stack. See Magnesium.
  • Don't expect a longevity miracle. The honest evidence supports K2 as a sensible adjunct for bone density and arterial flexibility, with several positive scan-and-marker trials behind it and several null ones — not as a proven extender of lifespan.
  • On warfarin: coordinate with your prescriber first. On a direct oral anticoagulant: no interaction is expected.

Further reading

  • Geleijnse JM et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr 2004.[51]
  • Knapen MHJ et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial. Thromb Haemost 2015.[52]
  • Knapen MHJ et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int 2013.[53]
  • Vossen LM et al. Two years of menaquinone-7 supplementation and coronary artery calcification: a randomized clinical trial (VitaK-CAC). JAMA Cardiol 2026.[54]
  • Diederichsen ACP et al. Vitamin K2 and D in patients with aortic valve calcification: a randomized double-blinded clinical trial (AVADEC). Circulation 2022.[55]
  • Rønn SH et al. The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia: a 3-year randomized, placebo-controlled trial. Osteoporos Int 2021.[56]
  • Shea MK et al. Vitamin K status, cardiovascular disease, and all-cause mortality: a participant-level meta-analysis of 3 US cohorts. Am J Clin Nutr 2020.[57]
  • Willeit K et al. Association of desphospho-uncarboxylated matrix Gla protein with incident cardiovascular disease and all-cause mortality: the Bruneck Study. Atherosclerosis 2022.[58]
  • Vermeer C. Vitamin K: the effect on health beyond coagulation — an overview. Food Nutr Res 2012.[59]
  • Sato T et al. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J 2012.[60]
  • Katagiri R et al. Association of soy and fermented soy product intake with total and cause specific mortality: prospective cohort study. BMJ 2020.[61]
  • Fujita Y et al. A 15-year cohort study of self-reported fermented soybean (natto) intake and all-cause mortality in elderly men. Clin Nutr ESPEN 2025.[62]
  • van Ballegooijen AJ et al. The synergistic interplay between vitamins D and K for bone and cardiovascular health. Int J Endocrinol 2017.[63]
  • Zhang T et al. Vitamin K2 in health and disease: a clinical perspective. Foods 2024.[64]
  • Zhang Z et al. The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis: a systematic review and meta-analysis. Front Endocrinol 2025.[65]
  • NIH Office of Dietary Supplements. Vitamin K — Health Professional Fact Sheet.[66]
  • Hasific S et al. Vitamin K(2) and D(3) Supplementation in Patients With Severe Coronary Artery Calcification: The DANCODE Trial. Circulation 2026.[67]
  • Hasific S et al. Effects of Vitamin K2 and D Supplementation on Coronary Artery Disease in Men: A RCT. JACC Adv 2023.[68]
  • Mott A et al. Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials. Osteoporos Int 2019.[69]
  • Theuwissen E et al. Effect of low-dose supplements of menaquinone-7 (vitamin K2 ) on the stability of oral anticoagulant treatment: dose-response relationship in healthy volunteers. J Thromb Haemost 2013.[70]
  • Brandenburg V et al. Vitamin K and vascular calcification: from biological plausibility to clinical realism. Clin Kidney J 2026.[71]

— § —